Literature DB >> 16460555

Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.

M D Kitzis1, F W Goldstein.   

Abstract

Vancomycin serum concentrations were determined for 1,737 patients treated with either 2 x 1 g of vancomycin or 4 x 500 mg daily (780 patients), according to current nomograms, or by continuous infusion (957 patients) with a loading dose (1 g) and a total of 2-6 g daily. Trough serum concentrations were determined after 36-48 h. Adequate serum levels for the treatment of a normal methicillin-resistant Staphylococcus aureus (MRSA) and a glycopeptide-intermediate S. aureus (GISA) were observed in 81% and 20.9% of patients, respectively. The data support theoretical arguments that higher and more sustained serum levels of vancomycin, obtained by continuous infusion, may enhance clinical efficacy.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16460555     DOI： 10.1111/j.1469-0691.2005.01306.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


  16 in total

1.  Therapeutic drug monitoring of antimicrobials.

Authors:  Jason A Roberts; Ross Norris; David L Paterson; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

2.  Traditional weight-based vancomycin dosing is inadequate in critically ill trauma patients.

Authors:  D D Yeh; M E Kutcher; K Lunghi
Journal:  Eur J Trauma Emerg Surg       Date:  2011-11-15       Impact factor: 3.693

Review 3.  Approaching and analyzing a large literature on vancomycin monitoring and pharmacokinetics.

Authors:  Patricia Lee; David DiPersio; Rebecca N Jerome; Arthur P Wheeler
Journal:  J Med Libr Assoc       Date:  2007-10

4.  Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin?

Authors:  Federico Pea; Pierluigi Viale
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

5.  Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Maya Hites; Marjorie Beumier; Sabino Scolletta; Frédérique Jacobs
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

6.  Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis.

Authors:  Lyndsay M van de Vijsel; Sandra A N Walker; Scott E Walker; Sharon Yamashita; Andrew Simor; Michelle Hladunewich
Journal:  Can J Hosp Pharm       Date:  2010-05

7.  Influence of vancomycin infusion methods on endothelial cell toxicity.

Authors:  Maryline Drouet; Feng Chai; Christine Barthélémy; Gilles Lebuffe; Bertrand Debaene; Bertrand Décaudin; Pascal Odou
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

8.  Failure of vancomycin continuous infusion against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.

Authors:  J M Entenza; T R Veloso; J Vouillamoz; M Giddey; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

9.  Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients.

Authors:  Federico Pea; Mario Furlanut; Camilla Negri; Federica Pavan; Massimo Crapis; Francesco Cristini; Pierluigi Viale
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

10.  Pulmonary versus systemic delivery of antibiotics: comparison of vancomycin dispositions in the isolated rat lung.

Authors:  María José de Jesús Valle; Francisco González López; Alfonso Domínguez-Gil Hurlé; Amparo Sánchez Navarro
Journal:  Antimicrob Agents Chemother       Date:  2007-08-06       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.